Innovent Bio (01801) announced that seven of its innovative products have been successfully included in the new edition of the National Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance Drug List (2026).
Products newly added to the National Medical Insurance Drug List include Xinermei® (mazdutide injection, a GCG/GLP-1 dual receptor agonist), Xinmeiyue® (picankibart injection, an IL-23p19 inhibitor), Daboxin® (ipilimumab N01 injection, a CTLA-4 inhibitor), and Weifutai® (quizartinib hydrochloride tablets, a type II FLT3 inhibitor). Products with newly added indications included in the list include Daboshu® (sintilimab injection, an anti-PD-1 monoclonal antibody) and Jiepali® (pirtobrutinib tablets, a non-covalent BTK inhibitor). Xinbile® (torecimab injection, a fully human PCSK9 monoclonal antibody) successfully renewed its contract.
The new edition of the National Medical Insurance Drug List will officially take effect on January 1, 2027. The successful inclusion of the company's seven innovative drugs in the National Medical Insurance Drug List covers disease areas with significant social burden, including oncology (colorectal cancer, renal cancer, hematological tumors), cardiovascular and metabolic diseases, and autoimmune diseases. The inclusion of these products in medical insurance will further enhance the accessibility and affordability of medications for patients, allowing more people to benefit.
With this, Innovent Bio's lineup of innovative drugs covered by medical insurance has expanded to 17, cumulatively benefiting over 20 million patients, continuously strengthening patient medication security through innovative achievements. Adhering to its corporate mission of "developing high-quality biologics that are affordable for ordinary people," Innovent Bio always puts patient needs at its core, actively responds to the "Healthy China 2030" strategic call, and takes concrete actions to support the construction of the national health security system and promote continuous improvement in health equity. The company will actively cooperate with the implementation of medical insurance policies in various coordinating regions, allowing high-quality innovative drugs to benefit thousands of households faster and more widely.